Brainstorm Cell Therapeutics Files 8-K
Ticker: BCLI · Form: 8-K · Filed: Apr 9, 2024 · CIK: 1137883
| Field | Detail |
|---|---|
| Company | Brainstorm Cell Therapeutics Inc. (BCLI) |
| Form Type | 8-K |
| Filed Date | Apr 9, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00005 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, financials
TL;DR
Brainstorm Cell Therapeutics filed an 8-K, likely containing financial updates or exhibits.
AI Summary
On April 9, 2024, Brainstorm Cell Therapeutics Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or transactions detailed in the provided excerpt.
Why It Matters
This filing indicates Brainstorm Cell Therapeutics Inc. is submitting required documentation to the SEC, which could include financial updates or exhibit filings relevant to investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K submission for financial statements and exhibits, not indicating any immediate material adverse events.
Key Players & Entities
- Brainstorm Cell Therapeutics Inc. (company) — Registrant
- April 9, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 001-36641 (filing_id) — SEC File Number
FAQ
What is the primary purpose of this 8-K filing by Brainstorm Cell Therapeutics Inc.?
The filing is primarily for 'Other Events' and 'Financial Statements and Exhibits', indicating routine SEC reporting.
When was this 8-K report filed?
The report was filed on April 9, 2024.
What is the state of incorporation for Brainstorm Cell Therapeutics Inc.?
Brainstorm Cell Therapeutics Inc. is incorporated in Delaware.
What is the SEC file number for Brainstorm Cell Therapeutics Inc.?
The SEC file number is 001-36641.
Does this filing indicate any specific new material events or transactions?
Based on the provided excerpt, the filing is categorized under 'Other Events' and 'Financial Statements and Exhibits', with no specific material events detailed.
Filing Stats: 480 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-04-09 06:05:19
Key Financial Figures
- $0.00005 — nge on which registered Common Stock, $0.00005 par value BCLI NASDAQ Stock Market L
Filing Documents
- tm2411382d1_8k.htm (8-K) — 24KB
- tm2411382d1_ex99-1.htm (EX-99.1) — 19KB
- 0001104659-24-044928.txt ( ) — 219KB
- bcli-20240409.xsd (EX-101.SCH) — 3KB
- bcli-20240409_lab.xml (EX-101.LAB) — 33KB
- bcli-20240409_pre.xml (EX-101.PRE) — 22KB
- tm2411382d1_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On April 9, 2024, Brainstorm Cell Therapeutics Inc. (the "Company") issued a press release announcing it received written agreement from the U.S. Food and Drug Administration, under a Special Protocol Assessment (SPA), on the design for a Phase 3b trial of NurOwn in amyotrophic lateral sclerosis (ALS). The Company will host a conference call and webcast at 8:00 a.m. Eastern Time on April 9, 2024 to further discuss this information. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Brainstorm Cell Therapeutics Inc., dated April 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRAINSTORM CELL THERAPEUTICS INC. Date: April 9, 2024 By: /s/ Chaim Lebovits Chaim Lebovits Chief Executive Officer